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Abstract
Purpose: Daily magnetic resonance (MR)eguided radiation has the potential to improve stereotactic
body radiation therapy (SBRT) for tumors of the liver. Magnetic resonance imaging (MRI) in-
troduces unique variables that are untested clinically: electron return effect, MRI geometric distortion,
MRI to radiation therapy isocenter uncertainty, multileaf collimator position error, and uncertainties
with voxel size and tracking. All could lead to increased toxicity and/or local recurrences with SBRT.
In this multi-institutional study, we hypothesized that direct visualization provided by MR guidance
could allow the use of small treatment volumes to spare normal tissues while maintaining clinical
outcomes despite the aforementioned uncertainties in MR-guided treatment.
Methods and materials: Patients with primary liver tumors or metastatic lesions treated with MR-
guided liver SBRT were reviewed at 3 institutions. Toxicity was assessed using National Cancer
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Institute Common Terminology Criteria for Adverse Events Version 4. Freedom from local
progression (FFLP) and overall survival were analyzed with the Kaplan-Meier method and c2 test.
Results: The study population consisted of 26 patients: 6 hepatocellular carcinomas, 2 chol-
angiocarcinomas, and 18 metastatic liver lesions (44% colorectal metastasis). The median follow-up
was 21.2 months. The median dose delivered was 50 Gy at 10 Gy/fraction. No grade 4 or greater
gastrointestinal toxicities were observed after treatment. The 1-year and 2-year overall survival in this
cohort is 69% and 60%, respectively. At the median follow-up, FFLP for this cohort was 80.4%.
FFLP for patients with hepatocellular carcinomas, colorectal metastasis, and all other lesions were
100%, 75%, and 83%, respectively.
Conclusions: This study describes the ﬁrst clinical outcomes of MR-guided liver SBRT. Treatment
was well tolerated by patients with excellent local control. This study lays the foundation for future
dose escalation and adaptive treatment for liver-based primary malignancies and/or metastatic
disease.
 2018 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Improved local and systemic treatments have led to
patients living longer in the setting of oligometastatic
disease.1,2 Ultimately, 50% of patients with solid tumor
malignancies develop liver metastases.3 In addition to
metastatic disease, the rate of primary liver malignancies
has tripled in the United States since the 1980s. There are
more than 39,000 primary liver malignancies in the United
States each year, with more than 27,000 deaths.4 Local
control of tumors within the liver is of pivotal importance
for improving outcomes for patients with cancer.5,6
There are a multitude of treatment options for primary
or secondary liver malignancies. Primary resection leads
to excellent local control and is the preferred treatment
modality. Only a small minority (<20%) of patients with
liver lesions have tumors amenable to primary
resection.7e10 Other treatment modalities such radio-
frequency ablation (RFA) and transarterial chemo-
embolization (TACE) are often limited by location (ie,
blood vessels, biliary tract, or liver dome) or tumor size.
RFA and TACE are invasive procedures and may be
associated with complications such as bleeding, infection,
or liver decompensation.11,12
Stereotactic body radiation therapy (SBRT) is a rela-
tively newer treatment modality for both primary and
metastatic liver lesions that delivers ablative radiation
doses to tumors. Single-institutional series of liver SBRT
have reported local control rates from 50% to 90%
depending on histologic type and tumor size.13e25 Clini-
cians are often restricted in the use of liver SBRT sec-
ondary to dose limitations of the uninvolved liver and
nearby normal organs (eg, kidney and bowel). To
appropriately limit normal tissue dose and account for
organ motion, multiple approaches have been developed,
including abdominal compression, ﬁducial marker
placement, and spirometric breathing control.26,27 Even
with surrogates of motion (ie, ﬁducial placement), many
liver tumors are not well visualized with x-ray imaging.
Magnetic resonance (MR)eguided treatment systems
allow real-time visualization and tracking of the tumor
itself, without using surrogate ﬁducial markers, and the
normal tissues during SBRT. The beneﬁts of MR-guided
treatment include improved soft tissue visualization and
tumor delineation. However, this technology is new, and
clinical outcomes with this technology are unproven.
Numerous obstacles must still be taken into account with
MR-guided radiation treatment planning: electron return
effect, MR imaging (MRI) geometric distortion, MRI to
radiation therapy (RT) isocenter uncertainty, multileaf
collimator (MLC) position error, and uncertainties with
voxel size and tracking. All could lead to toxicity and/or
local recurrences, particularly in the setting of small
margins.
In this multi-institutional study, we hypothesized that
direct visualization provided by MR guidance could allow
small treatment volumes to spare normal tissue while
maintaining clinical outcomes despite the aforementioned
uncertainties in MR-guided targeting. If clinical outcomes
are appropriate, this technology could then better be used
for dose escalation and potentially adaptive treatment.
Methods and materials
Eligible patients
As part of an institutional review boardeapproved
study, we reviewed patients between 2014 and 2017 at 3
institutions where they underwent MR-guided liver SBRT
with the MRIdian System (ViewRay Inc., Mountain
View, CA). Patients included had primary hepatocellular
carcinoma (HCC) of the liver or metastatic tumors to the
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liver for which surgery was not deemed an appropriate
option. Patients had either Child-Pugh A or early B and 1
to 3 liver lesions. No strict cutoff on lesion size was
placed on this population. Patients were not excluded if
they had previous local or regional therapy for their liver
lesion (ie, RFA, TACE).
Simulation
Real-time MR-guided SBRT delivery has been previ-
ously described.28 Brieﬂy, patients underwent 0.35 T
MRI on the MRIdian system. The treatment unit is an
open, split solenoid 0.35 T MRI scanner combined with 3
co-planar cobalt sources. Treatment is delivered via in-
tensity modulated RT. Patients underwent simulation
using a thorax board or Vac-Lok bag immobilization.
MRI coils were placed on the abdomen and directly under
the patient or outside an immobilization device. No
external respiratory motion management systems were
employed (ie, abdominal compression, spirometry, or
ﬁducial placement). True fast imaging (TRUFI) with
steady state free precession images were obtained (3.33
ms TR (repetition time), 1.43 ms TE (echo time), 60 ﬂip
angle, 3 mm slice thickness, 40  40  43 cm ﬁeld of
view). This resulted in T2-/T1-weighted images. Tumor
motion was evaluated with a real-time sagittal TRUFI
cine MRI sequence (2.1 ms TR, 0.91 ms TE, 60 ﬂip
angle, 7 mm slice thickness, 4 frames per second). The
patient’s breath hold reproducibility and tolerance was
evaluated at simulation. Patients underwent simulation
with a free-breathing scan to assess motion. Organ and
tumor motion was also assessed with a maximum inspi-
ratory breath hold and/or a shallow breathing technique. If
patients were unable to tolerate the simulation and cine
because of claustrophobia or inadequate breath hold, they
did not move forward with MR-based treatment.
Some patients who had metastatic lesions received
gadoxetic acid 20 minutes before simulation and each
treatment as previously described.28 On the same day as
MRI simulation, patients underwent a computed tomog-
raphy (CT) scan (free-breathing, 4-dimensional CT,
depending on institution preference) in the treatment po-
sition. This was obtained for electron density data for
dose calculations and aiding in outlining organs at risk
(OARs) and tumor. Two institutions performed gating
with maximum inspiratory breath hold for each patient
treated (N Z 16), and one institution used a modiﬁed
shallow internal target volume or exhale-based setup for
treatment (N Z 10). The basis of this choice was each
institution’s different approach to patient reproducibility
and comfort.
If tumor visualization was appropriate on simulation,
the tracking for treatment was performed on the lesion.
However, for some lesions, real-time sagittal TRUFI cine
MRI provided inadequate tracking to deliver treatment. In
this context, tracking was done using a surrogate anat-
omy: portal vein, liver lobe, and so on. Tracking was only
performed in 1 plane (sagittal) as standard practice at each
institution.
Treatment planning
A rigid registration of the 0.35 T simulation MRI scan
and the CT simulation was created for treatment planning.
The MRI was used as primary reference for contouring
for 2 institutions and the CT for 1 institution. However,
all available diagnostic information (TRUFI sequence, CT
scan, and diagnostic MRI if available) was used for the
contouring process. The gross tumor volume (GTV) was
delineated; no clinical target volume expansion was made
(GTV Z clinical target volume). A 2- to 5-mm isotropic
expansion was made to the planning target volume (PTV).
The margin was chosen based multiple factors: cobalt
source isocenter runout, MRI geometric distortion, un-
certainty of position of the 3 cobalt head isocenter, MRI
to RT isocenter, MLC position error, and uncertainties
with voxel size and tracking. These variables are inde-
pendent, and the sum of the square of these various un-
certainties leads to a 2-mm margin. Additional margin
was added (up to 3 mm) at the discretion of the treating
physician. The ﬁnal margin was individualized for each
patient, taking into account each patient’s individual
factors, and was not decided a priori.
The MRI and CT planning scans were imported into
the treatment planning system (ViewRay Inc). A Monte
Carlo treatment planning algorithm (ViewRay Inc) was
used with magnetic ﬁeld corrections to account for the
electron return effect. The treatment was prescribed to the
PTV volume. Treatment plans had 12 to 15 beams per
plan. Treatment planning goals varied across institutions
but included mean liver dose <13 to 15 Gy, >700 cm3 of
liver less than 15 Gy (liver-GTV), and stomach and bowel
V32-33 <0.5 cm3 (Table E1; available online at https://
doi.org/10.1016/j.adro.2018.08.005). These goals were
not strict cutoffs, and ﬁnal dosimetry balanced goals of
care versus toxicity. Typically, patients were treated with
50 Gy in 5 fractions, but this varied depending on OAR
and liver function. Typically we prescribed for at least
95% coverage of the prescribed dose unless restricted by
OARs. However, this was heterogenous across patients
and institutions. To be considered SBRT and included in
analysis, treatment must have been 30 Gy in total and
6 Gy/fraction. MR-guided RT plans have previously
been found to be similar to conventional linear accelerator
plans.29,30
Treatment delivery
At the time of treatment, patients underwent an MRI
scan for target and OAR alignment to the simulation. If
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gadoxetic acid contrast was used to enhance tumor visu-
alization at simulation, contrast was also given before
each treatment.
A boundary region was used if maximum inspiratory
breath hold was used for gating to ensure tumor was
within the proper position. This boundary was less than or
equal to the PTV. A sagittal TRUFI cine MRI sequence
(2.1 ms TR, 0.91 ms TE, 60 ﬂip angle, 7 mm slice
thickness 35  35 ﬁeld of view, 4 frames per a second)
was acquired for patients undergoing treatment. This al-
lows for tumor or tracking visualization during RT de-
livery via deformation/autosegmentation. A threshold of
90% to 95% of the GTV being within the boundary re-
gion was required for beam on. Patients were coached
with audio feedback to optimize tumor time within the
boundary structure. Daily adaptive treatment was not yet
commonly employed across institutions at the time of this
study.
The time in the treatment room was typically 40 to 60
minutes with 20 to 30 minutes of beam-on time. This
signiﬁcantly varied by dose rate of the cobalt sources
across institutions and breathing reproducibility for each
patient.
Follow-up
Patients were seen in follow-up every 3 to 6 months. A
typical follow-up included an interval history, physical
examination, appropriate imaging (MRI abdomen, posi-
tron emission tomography/CT, or CT of the abdomen/
pelvis), and laboratory values (eg, tumor makers and liver
enzymes). Freedom from local progression (FFLP) was
determined as a lack of an in-ﬁeld or marginal failure at
ﬁrst progression.13,31 FFLP and overall survival (OS)
were analyzed with Kaplan-Meier and a c2 test. Toxicity
was determined using National Cancer Institute Common
Terminology Criteria for Adverse Events Version 4 as a
chart review with a focus on grade 3 or higher toxicity.
All patients were assessed for toxicity, FFLP, and OS.
Secondary analysis of progression-free survival (PFS;
progression locally, regionally, or distally) was also
reported.
Results
A description of the patient population treated at all
institutions is shown in Table 1. A total of 26 patients
who were treated with MR-guided liver SBRT were
available for analysis. The majority of patients were male
(65%). The average age at the time of treatment was 70
years (range, 30-90 years). Twenty patients (77%) had
Child-Pugh A before treatment. The Child-Pugh status
was unknown for 6 patients before SBRT. A variety of
lesions were treated, including both metastatic and pri-
mary liver tumors: 8 colorectal adenocarcinoma, 6 HCC,
3 lung, 2 cholangiocarcinomas, 1 pancreas, 1 sarcoma, 1
head and neck, and 4 others. Given the variety of primary
and metastatic tumors, there was a wide array of local and
systemic pretreatment in this population. The median
PTV size was 98.2 cm3 (range, 13-2024). The majority of
patients were treated with 50 Gy (range, 30-60 Gy) in 5
fractions (6-12 Gy/fraction). Treatments typically had a
duty cycle (beam on time) of 80% to 85%. An example of
a typical treatment plan and dose distribution is shown in
Figure 1.
Treatment of this patient population was well tolerated.
There was minimal grade 3 gastrointestinal (GI) toxicity
(7.7%) (N Z 2) at a median follow-up of 21.2 months.
One patient developed a signiﬁcant hilar stricture
requiring a procedure. This patient had a large PTV size
(>250 cm3) and mean liver dose of 21.9 Gy (liver-GTV).
Another patient developed portal hypertension. Fifteen
patients had pre- and posttreatment Child-Pugh
Table 1 Summary of population treated with real-time
MR-guided liver SBRT
Characteristic n (%)
Age, median (range), y 70 (30-90)
Sex
Male 17 (65%)
Female 9 (35%)
Histologic diagnosis
Colorectal 8 (31%)
Hepatocellular carcinoma 6 (23%)
Lung 3 (12%)
Cholangiocarcinoma 2 (8%)
Pancreatic 1 (4%)
Sarcoma 1 (4%)
Head and neck 1 (4%)
Other 4 (15%)
Pretreatment Child-Pugh class
A 20 (76.9%)
B 0 (0%)
C 0 (0%)
NA 6 (23.1%)
PTV (cm3), median (range) 98.2 (13-2034)
Dose (Gy) to PTV, median (range) 50 (30-60)
Dose (Gy) per fraction, median (range) 10 (6-12)
Liver dose (Gy), median (range) 12.7 (3.2-21.9)
Posttreatment Child-Pugh class
A 13 (50%)
B 1 (4%)
C 1 (4%)
NA 11 (42%)
GI toxicity
Grade 3 2 (7.69%)
Grade 4-5 0 (0%)
Abbreviations: GI Z gastrointestinal; MR Z magnetic resonance;
NA Z not applicable; PTV Z planning target volume;
SBRT Z stereotactic body radiation therapy.
Median follow-up is 21.2 months. Liver mean excludes dose from
the gross tumor volume.
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available for analysis (Table E2; available online at
https://doi.org/10.1016/j.adro.2018.08.005). Two patients
had a drop in Child-Pugh score in this population. A
patient with a renal cell carcinoma treated to 40 Gy in 5
fractions had a drop in Child-Pugh score from A to B.
This patient had a large-volume tumor (>900 cm3) that
led to a higher than average liver mean dose of 18.9 Gy
(liver-GTV). The second patient with a drop in Child-
Pugh from A to C had an HCC with 4 prior TACE pro-
cedures. This patient was treated 50 Gy in 10 fractions
and also had a high mean liver dose (20 Gy) (liver-GTV).
This was the same patient who developed portal hyper-
tension. No grade 4 or 5 toxicity was observed in this
cohort. There was minimal to no skin toxicity in this
group despite the use of a cobalt-based system.
FFLP and OS were analyzed for this group. At the
median follow-up (21.2 months), the FFLP was 80.4%
(Fig 2A). The 1-year and 2-year OS in this cohort was
69% and 60%, respectively (Fig 2B). Two patients had
very short follow-up (approximately 2 months) with 1
patient dying 2 months after liver SBRT secondary to
rapid distant progressive disease. There is no indication
that patient died from radiation-related toxicity. The other
patient was lost to follow-up.
FFLP varied based on tumor histology (Fig 3). The
FFLP rates for patients with HCC were 100%. Patients
with colorectal metastasis had a 75% FFLP. For all other
primary or metastatic tumors combined, the FFLP was
83%. There were 2 local failures (transitional cell carci-
noma of the renal pelvis and a renal cell carcinoma)
among these 12 patients. Colorectal versus noncolorectal
tumor histology had a higher frequency of local pro-
gression after SBRT with a trend toward signiﬁcance (c2
[N Z 26], P Z .36). The PFS (local, regional, or distant
progression) in the entire cohort was 35% (9 patients
without known progressive disease). The PFS for HCC,
colorectal lesions, and other histologic tumor types was
33%, 25%, and 42%, respectively.
Discussion
Treatment for liver SBRT is technically challenging,
involving high doses, steep gradients, small margins, and
moving tumors. MR guidance holds promise to ensure
treatment accuracy through improved setup and direct
visualization of treatment targets. As with any new
technology, new sources of error and uncertainties exist.
Notable uncertainties for MR-guided SBRT include
electron return effect, MRI geometric distortion, MRI to
RT isocenter uncertainty, MLC position error, and un-
certainties with voxel size and tracking. It is important to
Figure 1 Patient with liver metastasis with images showing
simulation on the MRIdian system with the true fast imaging
sequence and the dose distribution.
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Figure 2 Analysis of (A) freedom from local progression
(FFLP) and (B) overall survival. Twenty-six patients were
available for analysis. FFLP and OS were analyzed for this
group. At the median follow-up (21.2 months), the FFLP was
80.4% (A). The 1-year and 2-year OS in this cohort was 69%
and 60%, respectively (B).
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evaluate these clinically because they could lead to
increased local recurrences and/or toxicity with SBRT.
This study is the ﬁrst to describe the clinical outcomes
of liver SBRT with real-time MR guidance. In this cohort
the FFLP and OS of primary and metastatic liver tumors
treated with MR-guided treatment are consistent with
those previously reported in the literature (FFLP 80.4%
and 2-year OS 60%). This includes the slightly lower
local control rate of patients with colorectal metastasis
(75%) compared with primary liver tumors or other
metastatic lesions.13e19,21,24,25 These results provide
strong clinical evidence that MR-guided treatment is ac-
curate in delivery in the clinical context of liver SBRT.
Minimal toxicity was identiﬁed in this treatment
cohort. There were a small number of grade 3 GI toxic-
ities (7.7%). No grade 4 or grade 5 toxicity was found
with MR-guided treatment. Only 2 patients experienced a
drop in Child-Pugh category. Most patients with grade 3
GI toxicity or a drop in Child-Pugh had previous multiple
local therapies and/or high liver mean doses with treat-
ment. This experience is in contrast to other reports of
liver SBRT that sometimes indicate a drop in Child-Pugh
in 20% to 30% of patients in addition to rates of 1% to
10% for grade 4 or 5 toxicity.32,33
As expected, despite cobalt sources, SBRT planned
with multiple beam angles produced no signiﬁcant skin
reactions in this treatment population. Patients in the
present study tolerated treatment extremely well,
including a patient aged 90 years. These results are
consistent with the literature reporting that SBRT is well
tolerated with minimal adverse impact on quality of life.34
The majority of radiation-induced liver disease occurs
within the ﬁrst 2 to 9 months after treatment.35,36 Given
our median follow-up of 21 months, we were likely able
to capture the majority of any toxicity from MR-guided
treatment.
The low toxicity found in this study is likely related to
several factors, including the use of small treatment vol-
umes and the ability to visualize tumors, liver, and other
OARs during treatment (MRI cine). Visualization helps
ensure greater accuracy and reproducibility in delivering
the prescribed dose to the target. This also allows the use
of small PTV margins that may be individualized based
on patient characteristics (ie, reproducible breath hold)
and characteristics of the physical aspects of the machine
(eg, MRI geometric distortion, target tracking, MLC po-
sition error).
The cine MRI allows for tumor tracking in a single
sagittal plane during treatment. Importantly, previous
research has found that the majority of liver tumor motion
is in the superoinferior and anteroposterior directions.37
Therefore we are able to visualize the majority of tumor
motion or surrogate anatomy during treatment. However,
this leaves the possibility of unexpected tumor or patient
motion in the medial/lateral dimension going unrecog-
nized. The co-planar orientation of the beams results in
the least gradient in the axial plane, which helps address
uncertainty. The inherent penumbra of cobalt in this
MRIdian system also helps address uncertainty that ac-
companies tumor tracking. However, this feature also
limits the conformality of our treatment plans compared
with a linear accelerator (linac)ebased approach. Small
margins help compensate for the penumbra of the cobalt-
based compared with traditional approaches with larger
PTV expansions. Linac-based MR-guided RT is now
clinically available. Balancing tightly conformal treat-
ment, MR-guided linac-based approaches and PTV
margin size will be important moving forward.
The small sample size, short follow-up, retrospective
analysis, and heterogeneous group of patients are known
limitations of this analysis. However, the study aimed to
determine if we could overcome the unique obstacles of
MR-guided treatment to deliver accurate and well-
tolerated radiation in the technically challenging setting
of liver SBRT. This study helps establish that MR-guided
treatment is well tolerated and effective in the clinic
despite these obstacles. Although MR-guided treatment
may be limited to certain facilities, it is important to note
that this technology is increasing across the United States
and abroad. With the dissemination of this technology,
safely and appropriately delivering liver SBRT will be
imperative.
Despite the success of MR-guided treatment for most
patients, local failures were noted in our treatment cohort.
A review of patients with local progression does reveal
that normal organs at risk (eg, bowel, kidney) may be a
limiting factor in delivering ablative radiation doses to
liver tumors. An example of such a failure is a patient
with a colorectal metastatic lesion in the medial lobe of
the liver. Figure 4 shows the coronal view of the TRUFI
sequence of the patient’s MR-guided radiation plan. The
nearby bowel limited dose to the inferior aspect of the
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Figure 3 Freedom from local progression (FFLP) varied by
histologic diagnosis. Patients with hepatocellular carcinoma had
a 100% FFLP. Patients with colorectal metastasis and all other
histologic diagnoses had an FFLP of 75% and 83%, respec-
tively. The FFLP was determined as of the most recent follow-
up for each patient within this cohort. Colorectal metastasis
trended toward decreased local control compared with other
histologic tumor types (c2 [N Z 26], P Z .36).
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tumor, and the heart limited dose to the superior aspect of
the tumor. This may have contributed to the development
of a local failure for this patient (Fig 4B). Studies of dose
escalation indicate improved local control at higher doses
of liver SBRT.38 However, dose escalation to tumors may
be limited secondary to nearby organs at risk. Adaptive
MR-guided RT was not yet standard in our clinics when
this patient was treated. If this had been available, this
patient may have beneﬁted from such an approach.
Per our review of patients, there remains signiﬁcant
interfractional motion of these organs as risk, as well as
heterogeneity across patients (unpublished). With real-
time visualization, we can potentially adapt treatment
daily and potentially better personalize RT doses.
Particularly for tumors near the liver edge, direct visual-
ization during treatment allows conﬁdence to treat with
high doses near organs such as bowel or stomach, where
position uncertainty could lead to a dose that exceeds their
tolerance. This may be of particular importance for tu-
mors with slightly lower local control rates. For example,
the FFLP for this population with colorectal metastasis
was 75%, these patients may beneﬁt from further dose
escalation.38 These colorectal patients also stand to gain
the most because in some patients truly ablative control
may offer the possibility of curative treatment similar to
surgical resection.
The ability to adapt treatment to these tumor or
anatomic changes on a daily basis with direct MRI
visualization provides conﬁdence in the dose to OARs,
suggesting the feasibility of further dose-escalation
studies. The ability to adapt treatment daily on the
MRIdian system based on functional MRI sequences is
currently in development and may also work to improve
outcomes. This requires a detailed quality assurance
process and recontouring OARs and targets each day.39,40
Real-time MR guidance and daily plan adaptation pro-
vides the opportunity for further dose escalation that can
be systemically explored in controlled clinical trials that
are currently in development in our institutions. This
multi-institutional study of a ﬁrst experience with MR-
guided liver SBRT will lay the foundation for further
prospective studies.
Conclusion
MR-guided liver SBRT provides local control rates
consistent with those in the literature for metastatic and
primary lesions with minimal toxicity. This suggests
currently available MR-guided treatments account well
for new sources of uncertainty associated with MR-
guided treatment in a challenging clinical context. MR
guidance allows the delivery of liver SBRT without the
use of indirect or invasive means of respiratory motion
management such as ﬁducial placement, spirometric
breathing control, or abdominal compression. The limited
toxicity reported to date with real-time MR-guided liver
SBRT opens the opportunity to investigate plan adapta-
tion and dose escalation to further improve outcomes for
patients with tumors near critical organs.
Supplementary data
Supplementary material for this article (https://doi.
org/10.1016/j.adro.2018.08.005) can be found at www.
advancesradonc.org.
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